---
title: "SHARPS TECHNOLOGY INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.289 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265981508.md"
datetime: "2025-11-14T21:00:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265981508.md)
  - [en](https://longbridge.com/en/news/265981508.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265981508.md)
generator: "portal-rs"
---

# SHARPS TECHNOLOGY INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.289 M

Revenue: As of FY2025 Q3, the actual value is USD 2.289 M.

EPS: As of FY2025 Q3, the actual value is USD -4.33.

EBIT: As of FY2025 Q3, the actual value is USD -102.71 M.

### Medical Device Packaging Segment

-   **Net Revenue**: $306,344 for the nine months ended September 30, 2025.
-   **Total Cost of Goods Manufactured**: $2,508,027 for the nine months ended September 30, 2025.
-   **Gross Margin (Loss)**: - $2,201,683 for the nine months ended September 30, 2025.
-   **Research and Development**: $295,579 for the nine months ended September 30, 2025, a decrease from $523,347 for the same period in 2024.
-   **Selling, General and Administrative**: $114,571,809 for the nine months ended September 30, 2025, an increase from $5,257,015 for the same period in 2024.
-   **Impairment of Long-Lived Fixed Assets**: $7,497,669 for the nine months ended September 30, 2025.

### Digital Assets Segment

-   **Staking Revenue**: $2,205,423 for the nine months ended September 30, 2025.
-   **Transaction Expenses**: $810,861 for the nine months ended September 30, 2025.
-   **Realized and Unrealized Gains on Digital Assets**: $15,499,742 for the nine months ended September 30, 2025.
-   **Derivative Gain (Loss), Net**: - $4,378,749 for the nine months ended September 30, 2025.

### Corporate

-   **Net Interest Income (Expense)**: - $461,551 for the nine months ended September 30, 2025, compared to - $46,503 for the same period in 2024.
-   **FMV Adjustment for Warrants**: $12,295,842 for the nine months ended September 30, 2025, compared to $2,088,747 for the same period in 2024.
-   **Other Income (Expense)**: - $1,000,090 for the nine months ended September 30, 2024.
-   **Foreign Currency Gain (Loss)**: $371,741 for the nine months ended September 30, 2025, compared to - $31,566 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue its focus on the marketing and distribution of syringe products and related drug-delivery systems, while no longer engaging in research, design, and manufacturing activities.
-   **Non-Core Business**: The company has adopted a digital asset treasury strategy focused on accumulating Solana (SOL) and has begun exploring strategic acquisitions and/or investments globally.
-   **Share Repurchase Program**: The company has approved a share repurchase program providing for the repurchase of up to $100,000,000 of its outstanding shares of Common Stock.

### Related Stocks

- [STSSW.US](https://longbridge.com/en/quote/STSSW.US.md)
- [SKYAW.US](https://longbridge.com/en/quote/SKYAW.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**